Literature DB >> 21082977

Hydroxyurea use in sickle cell disease: the battle with low prescription rates, poor patient compliance and fears of toxicities.

Amanda M Brandow, Julie A Panepinto.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 21082977      PMCID： PMC3793890          DOI： 10.1586/ehm.10.22

Source DB:  PubMed          Journal:  Expert Rev Hematol        ISSN： 1747-4094            Impact factor:   2.929


× No keyword cloud information.
  47 in total

1.  Pain at home in sickle cell disease: an underrecognized problem.

Authors:  Winfred C Wang
Journal:  J Pediatr Hematol Oncol       Date:  2002-11       Impact factor: 1.289

2.  Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment.

Authors:  Martin H Steinberg; Franca Barton; Oswaldo Castro; Charles H Pegelow; Samir K Ballas; Abdullah Kutlar; Eugene Orringer; Rita Bellevue; Nancy Olivieri; James Eckman; Mala Varma; Gloria Ramirez; Brian Adler; Wally Smith; Timothy Carlos; Kenneth Ataga; Laura DeCastro; Carolyn Bigelow; Yogen Saunthararajah; Margaret Telfer; Elliott Vichinsky; Susan Claster; Susan Shurin; Kenneth Bridges; Myron Waclawiw; Duane Bonds; Michael Terrin
Journal:  JAMA       Date:  2003-04-02       Impact factor: 56.272

3.  Fertility in males with sickle cell disease.

Authors:  D N Osegbe; O Akinyanju; E O Amaku
Journal:  Lancet       Date:  1981-08-08       Impact factor: 79.321

4.  Fertility studies in sickle cell disease: semen analysis in adult male patients.

Authors:  V O Agbaraji; R B Scott; S Leto; L W Kingslow
Journal:  Int J Fertil       Date:  1988 Sep-Oct

5.  Home management of pain in sickle cell disease: a daily diary study in children and adolescents.

Authors:  Carlton Dampier; Elizabeth Ely; Darcy Brodecki; Patricia O'Neal
Journal:  J Pediatr Hematol Oncol       Date:  2002-11       Impact factor: 1.289

6.  Five years of experience with hydroxyurea in children and young adults with sickle cell disease.

Authors:  A Ferster; P Tahriri; C Vermylen; G Sturbois; F Corazza; P Fondu; C Devalck; M F Dresse; W Feremans; K Hunninck; M Toppet; P Philippet; C Van Geet; E Sariban
Journal:  Blood       Date:  2001-06-01       Impact factor: 22.113

7.  Maintenance of elevated fetal hemoglobin levels by decitabine during dose interval treatment of sickle cell anemia.

Authors:  Joseph DeSimone; Mabel Koshy; Louise Dorn; Donald Lavelle; Linda Bressler; Robert Molokie; Nasrin Talischy
Journal:  Blood       Date:  2002-06-01       Impact factor: 22.113

8.  Definitions of the phenotypic manifestations of sickle cell disease.

Authors:  Samir K Ballas; Susan Lieff; Lennette J Benjamin; Carlton D Dampier; Matthew M Heeney; Carolyn Hoppe; Cage S Johnson; Zora R Rogers; Kim Smith-Whitley; Winfred C Wang; Marilyn J Telen
Journal:  Am J Hematol       Date:  2010-01       Impact factor: 10.047

9.  Pain in children and adolescents with sickle cell disease: a descriptive study.

Authors:  G A Walco; C D Dampier
Journal:  J Pediatr Psychol       Date:  1990-10

10.  Sustained long-term hematologic efficacy of hydroxyurea at maximum tolerated dose in children with sickle cell disease.

Authors:  Sherri A Zimmerman; William H Schultz; Jacqueline S Davis; Chrisley V Pickens; Nicole A Mortier; Thad A Howard; Russell E Ware
Journal:  Blood       Date:  2003-11-20       Impact factor: 22.113
View more
  33 in total

1.  Association between hospital admissions and healthcare provider communication for individuals with sickle cell disease.

Authors:  Robert M Cronin; Manshu Yang; Jane S Hankins; Jeannie Byrd; Brandi M Pernell; Adetola Kassim; Patricia Adams-Graves; Alexis A Thompson; Karen Kalinyak; Michael DeBaun; Marsha Treadwell
Journal:  Hematology       Date:  2020-12       Impact factor: 2.269

2.  Hydroxyurea is associated with lower costs of care of young children with sickle cell anemia.

Authors:  Winfred C Wang; Suzette O Oyeku; Zhaoyu Luo; Sheree L Boulet; Scott T Miller; James F Casella; Billie Fish; Bruce W Thompson; Scott D Grosse
Journal:  Pediatrics       Date:  2013-09-02       Impact factor: 7.124

3.  Do difficulties in swallowing medication impede the use of hydroxyurea in children?

Authors:  ElShadey Bekele; Courtney D Thornburg; Amanda M Brandow; Mukta Sharma; Arlene M Smaldone; Zhezhen Jin; Nancy S Green
Journal:  Pediatr Blood Cancer       Date:  2014-04-17       Impact factor: 3.167

4.  An Investigation of Structure-Activity Relationships of Azolylacryloyl Derivatives Yielded Potent and Long-Acting Hemoglobin Modulators for Reversing Erythrocyte Sickling.

Authors:  Abdelsattar M Omar; Osheiza Abdulmalik; Mohini S Ghatge; Yosra A Muhammad; Steven D Paredes; Moustafa E El-Araby; Martin K Safo
Journal:  Biomolecules       Date:  2020-11-02

5.  Increased risk of leukemia among sickle cell disease patients in California.

Authors:  Ann Brunson; Theresa H M Keegan; Heejung Bang; Anjlee Mahajan; Susan Paulukonis; Ted Wun
Journal:  Blood       Date:  2017-08-22       Impact factor: 22.113

Review 6.  L-glutamine for sickle cell disease: Knight or pawn?

Authors:  Alina Sadaf; Charles T Quinn
Journal:  Exp Biol Med (Maywood)       Date:  2020-01-27

Review 7.  Reducing Health Care Disparities in Sickle Cell Disease: A Review.

Authors:  LaTasha Lee; Kim Smith-Whitley; Sonja Banks; Gary Puckrein
Journal:  Public Health Rep       Date:  2019-10-10       Impact factor: 2.792

8.  Intentional and unintentional nonadherence to hydroxyurea among people with sickle cell disease: a qualitative study.

Authors:  Jason R Hodges; Shannon M Phillips; Sarah Norell; Chinonyelum Nwosu; Hamda Khan; Lingzi Luo; Sherif M Badawy; Allison King; Paula Tanabe; Marsha Treadwell; Lucia Rojas Smith; Cecelia Calhoun; Jane S Hankins; Jerlym Porter
Journal:  Blood Adv       Date:  2020-09-22

9.  Decreased fetal hemoglobin over time among youth with sickle cell disease on hydroxyurea is associated with higher urgent hospital use.

Authors:  Nancy S Green; Deepa Manwani; Mahvish Qureshi; Karen Ireland; Arpan Sinha; Arlene M Smaldone
Journal:  Pediatr Blood Cancer       Date:  2016-08-30       Impact factor: 3.167

10.  Proteinuria in adults with sickle-cell disease: the role of hydroxycarbamide(hydroxyurea) as a protective agent.

Authors:  Geraldo B Silva Junior; Ana Patrícia F Vieira; Amanda X Couto Bem; Marília P Alves; Gdayllon C Meneses; Alice M C Martins; Sonia M H A Araújo; Alexandre V Libório; Elizabeth F Daher
Journal:  Int J Clin Pharm       Date:  2014-06-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.